Survodutide Overview
Mechanism of Action
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist. Combines GLP-1-mediated appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation. The glucagon component specifically targets liver fat reduction, making it particularly promising for MASLD/NASH.
~7 days
Timing
Same day each week
Injection Site
Subcutaneous
Food
No restrictions
Common Stacks
- Lifestyle modification
- B12 supplementation
Survodutide Dosing Protocol
Initiation
4 weeks0.3 mg weekly
Starting dose.
Titration
4 weeks per stepIncrease monthly
0.3 → 0.6 → 1.2 → 2.4 → 4.8 mg.
Maintenance
Ongoing2.4–4.8 mg weekly
Target based on response.
Survodutide Expected Timeline
Week 1–4
Appetite reduction; GI adaptation
Month 1–3
Progressive weight loss; liver fat reduction
Month 3–6
Significant weight and liver fat reduction
Month 6+
Potential NASH resolution
Survodutide Side Effects
Nausea
Diarrhea
Vomiting (dose-dependent)
Decreased appetite
Survodutide Research Studies
Survodutide for MASH (SYNCHRONIZE-1)
Sanyal AJ, et al. — N Engl J Med (2024)
Phase 2: survodutide achieved NASH resolution in up to 83% of patients, with 65% achieving fibrosis improvement — among the best NASH therapy results.
PubMed: 38856224Survodutide FAQ
What makes survodutide special for liver disease?
The glucagon component targets hepatic fat oxidation. Phase 2 showed 83% NASH resolution — better than GLP-1-only drugs.
Survodutide vs retatrutide?
Survodutide is dual (GLP-1 + glucagon), retatrutide is triple (+ GIP). Both have glucagon for liver fat. Survodutide has more NASH-specific data.